<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560468</url>
  </required_header>
  <id_info>
    <org_study_id>HSM 12-00045</org_study_id>
    <secondary_id>12-0123</secondary_id>
    <nct_id>NCT01560468</nct_id>
  </id_info>
  <brief_title>Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection</brief_title>
  <official_title>Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Schiano, Thomas D., MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>iTherX Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Schiano, Thomas D., MD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety and tolerability of HCV Entry Inhibitor ITX 5061 in Liver&#xD;
      Transplant Recipients with Hepatitis C infection. The investigators hypothesize that ITX 5061&#xD;
      oral monotherapy will be safe in adults during and after liver transplantation and that&#xD;
      therapy will also inhibit HCV infection of newly transplanted livers in adults with prior HCV&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will receive 28 days of ITX 5061 beginning at the time of transplant.&#xD;
&#xD;
      Dosing of ITX 5061 is as follows:&#xD;
&#xD;
      Day of Transplant prior to surgery: ITX 5061 300 mg Day of Transplant following surgery: ITX&#xD;
      5061 300 mg Post-Operative Days 1-6: ITX 5061 300 mg Post-Operative Days 7-27: ITX 5061 150&#xD;
      mg&#xD;
&#xD;
      Subjects will be monitored for HCV RNA levels, HDL cholesterol and ITX 5061 drug&#xD;
      concentration levels.&#xD;
&#xD;
      A liver biopsy will be performed at 6 months post-transplant to assess for histological signs&#xD;
      of HCV recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Financial Reasons&#xD;
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of HCV recurrence post-transplant</measure>
    <time_frame>28 days</time_frame>
    <description>We hypothesize that ITX 5061 oral monotherapy will be safe in adults during and after liver transplantation and will inhibit HCV infection of newly transplanted livers in adults with prior HCV infection. The number of treated subjects who are infected at 28 days post-transplant will be compared to the historical control rate (95%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum HCV RNA</measure>
    <time_frame>3 months after transplant</time_frame>
    <description>To determine the change in serum HCV RNA from study entry to end of dosing (28 days) and 3 month follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of ITX 5061</measure>
    <time_frame>28 days</time_frame>
    <description>To assess trough levels of plasma ITX 5061 throughout the dosing period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral dynamics of serum HCV RNA</measure>
    <time_frame>24 hours post-transplant</time_frame>
    <description>To characterize the viral dynamics of serum HCV RNA levels during the first 24 hours post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential changes in plasma HCV E2</measure>
    <time_frame>28 days</time_frame>
    <description>To characterize potential changes in plasma HCV E2 (HCV envelope protein) regions in the setting of ITX 5061 administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>ITX 5061</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ITX 5061 for 28 days beginning at the time of liver transplantation for hepatitis C virus. 300mg will be administered on the day of surgery and for one week post transplant, followed by 150mg for an additional 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITX 5061</intervention_name>
    <description>300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.</description>
    <arm_group_label>ITX 5061</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-72&#xD;
&#xD;
          -  Patients accepted onto waiting list for liver transplantation for HCV related liver&#xD;
             disease and receiving a deceased donor liver allograft&#xD;
&#xD;
          -  HCV RNA (+) at time of listing for transplantation. All HCV genotypes will be eligible&#xD;
&#xD;
          -  Patients with HCC and those receiving hepatitis B core (+) donor livers will be&#xD;
             eligible&#xD;
&#xD;
          -  Standard immunosuppression protocol with tacrolimus, corticosteroid taper, and&#xD;
             mycophenolate mofetil&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Viral co-infection (HBV/HIV)&#xD;
&#xD;
          -  Receipt of a HCV (+) donor allograft&#xD;
&#xD;
          -  Patients undergoing retransplantation for recurrent HCV&#xD;
&#xD;
          -  Multivisceral transplantation&#xD;
&#xD;
          -  Patients receiving anti-viral therapy at the time of LT&#xD;
&#xD;
          -  Live donor liver transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas D Schiano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus Infection</keyword>
  <keyword>Liver Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

